Sequential Treatment With Azacitidine and Lenalidomide for Relapsed and Refractory Patients With Acute Myeloid Leukemia
Phase of Trial: Phase II
Latest Information Update: 10 Oct 2019
Price : $35 *
At a glance
- Drugs Azacitidine (Primary) ; Azacitidine (Primary) ; Lenalidomide (Primary)
- Indications Acute myeloid leukaemia
- Focus Therapeutic Use
- 04 Dec 2018 Results assessing Computational Biology Modeling Analysis of Azacitidine (AZA) and Lenalidomide in acute myeloid leukemia patients, presented at the 60th Annual Meeting and Exposition of the American Society of Hematology.
- 12 Dec 2017 Results presented at the 59th Annual Meeting and Exposition of the American Society of Hematology
- 03 Jan 2017 Status changed from active, no longer recruiting to completed.